Investor Newsletter July 2023 


Amplia has published its new Investor Newsletter today. 

This edition includes an update from our ACCENT trial - Amplia’s Phase 1b/2a clinical trial of AMP945 in people with advanced pancreatic cancer; a recap of the exciting FOLFIRINOX data from the Garvan Institute; a peek into our collaboration with the CSIRO investigating opportunities in wound healing; and more.  

Read the newsletter here.